Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective Effects of Estradiol on Disease Progression in a Murine Model of Fuchs Endothelial Corneal Dystrophy.

Investigative ophthalmology & visual science·2026
Same author

Advancements and Innovations in Keratoconus Management: A Review of Current Practices.

Journal of clinical medicine·2025
Same author

Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy.

Cells·2025
Same author

Heterozygous Tcf4 Deficiency Mitigates Fuchs Endothelial Corneal Dystrophy Progression in a Mouse Model.

Investigative ophthalmology & visual science·2025
Same author

Analysis of factors influencing refractive error in Fuchs eyes undergoing Descemet membrane endothelial keratoplasty triple procedure.

The British journal of ophthalmology·2024
Same author

TCF4 trinucleotide repeat expansions and UV irradiation increase susceptibility to ferroptosis in Fuchs endothelial corneal dystrophy.

Redox biology·2024
Same journal

Efficacy of Punctal Occlusion Techniques in Tear Drainage Disorders: A Systematic Review and Meta-Analysis.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Ophthalmic Implications of Ehlers-Danlos Syndrome.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Diagnostic Value of Pupil Involvement and Yield of Vascular Imaging in Isolated Third Cranial Nerve Palsy: A 10-Year Retrospective Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Short-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Chemical and Thermal Ocular Burns in Children: A Retrospective Single-Center Study of Etiology, Clinical Characteristics, and Outcomes.

Clinical ophthalmology (Auckland, N.Z.)·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

5.2K

Fuchs endothelial corneal dystrophy: current perspectives.

Gustavo Vedana1, Guadalupe Villarreal1, Albert S Jun1

  • 1Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Clinical Ophthalmology (Auckland, N.Z.)
|March 4, 2016
PubMed
Summary
This summary is machine-generated.

Fuchs endothelial corneal dystrophy (FECD) is a common cause of vision loss. Recent advances improve understanding of its genetics, pathophysiology, and treatment, including endothelial keratoplasty.

Keywords:
Descemet’s membrane endothelial keratoplastyDescemet’s stripping automated endothelial keratoplastyFuchs endothelial corneal dystrophycorneal endothelial cellcorneal transplantationendothelial keratoplasty

More Related Videos

Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
04:48

Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures

Published on: November 22, 2024

986
Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss
06:23

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss

Published on: April 24, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 24, 2026

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

5.2K
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
04:48

Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures

Published on: November 22, 2024

986
Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss
06:23

Development of a Noninvasive, Laser-Assisted Experimental Model of Corneal Endothelial Cell Loss

Published on: April 24, 2020

6.0K

Area of Science:

  • Ophthalmology
  • Genetics
  • Cell Biology

Background:

  • Fuchs endothelial corneal dystrophy (FECD) is the most prevalent corneal dystrophy, often leading to significant vision impairment.
  • Key pathological features include corneal endothelial cell loss and abnormal Descemet's membrane excrescences, progressing to affect all corneal layers.
  • Disease progression is driven by endothelial barrier and pump dysfunction, alongside cell death induced by oxidative and unfolded protein stress.

Purpose of the Study:

  • To provide a comprehensive overview of current knowledge regarding FECD.
  • To highlight recent advancements in understanding the clinical presentation, underlying pathophysiology, and genetic basis of FECD.
  • To discuss emerging treatments, including updated endothelial keratoplasty techniques and potential future therapeutic strategies.

Main Methods:

  • Literature review of clinical, pathological, genetic, and therapeutic research on FECD.
  • Analysis of recent studies on endothelial keratoplasty outcomes.
  • Synthesis of findings on the genetic factors, particularly TCF4 gene alterations, implicated in FECD.

Main Results:

  • FECD involves progressive endothelial cell loss and structural corneal changes.
  • Genetic factors, notably the transcription factor 4 (TCF4) gene, play a significant role in the majority of FECD cases.
  • Endothelial keratoplasty represents the current gold standard for definitive FECD treatment, with ongoing refinements.

Conclusions:

  • Significant progress has been made in elucidating the complex mechanisms driving FECD.
  • Understanding the genetic underpinnings and cellular stresses is crucial for developing targeted therapies.
  • Continued research into novel treatments and surgical techniques promises to improve outcomes for patients with FECD.